As GSK’s share price drops 15%, should I buy, sell, or hold?

GSK’s share price has fallen on negative developments for two of its drugs, but it still has a strong core business with excellent growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK’s (LSE: GSK) share price action raises the classic investor question for me of how to proceed. Should I keep my holding, maybe even add to it, or sell out?

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALL18 Jul 201918 Jul 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Why is it down?

The first thing I need to do is to work out why it has dropped 15% since its 15 May 12-month traded high of £18.12.

There are two reasons that I can see. First, a US court ruled on 31 May that 70,000+ lawsuits can move forward to trial. These allege a connection between GSK’s Zantac drug and cancer. This raises the risk of very high compensation awarded against GSK if its further appeals against the action are unsuccessful.

Should you invest £1,000 in Rolls-Royce right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Rolls-Royce made the list?

See the 6 stocks

And second, 26 June saw the US Centers for Disease Control and Prevention (CDC) no longer recommend Arexvy RSV vaccine for people under 60.

Earlier in the month, the US Food and Drug Administration had approved the use of this vaccine for those aged 50 to 59. It is the first shot endorsed for that age group.

Nonetheless, the CDC’s decision is likely to reduce Arexvy sales, unless it changes its view. GSK had expected the vaccine to generate annual sales of more than £3bn.

Are there any offsetting factors?

My experience as a former investment bank trader tells me that I should not assume either of these negative factors will improve. If they do, it will be a bonus.

So, what else is there in GSK that might offset these negative developments over the long term?

Its Blenrep drug was found on 7 March to help in extending life in plasma cell cancer patients. Citigroup analysts expect around £2.5bn of peak risk-adjusted sales of the drug.

Its full-year 2023 results — before the latest Zantac and Arexvy developments – contained upgrades in its long-term outlook.

Adjusted operating profit was forecast to grow at a compound annual rate of 11%+ to 2026 on an annual sales rise of 7%+. By 2031, it expected sales of more than £38bn.

No new financial statement has been released regarding the impact of the Zantac and Arexvy news. However, GSK will announce its Q2 2024 results on 31 July.

Relative share valuation now

Its shares trade on the key price-to-earnings ratio (P/E) at 13.7. This is the lowest among its peers, which have an average P/E of 29.9.

This group comprises Johnson & Johnson at 21.3, Hikma Pharmaceuticals at 28, Hutchmed at 31.8, and AstraZeneca at 38.4. Consequently, on this basis, GSK looks very undervalued.

Moreover, analysts’ estimates currently say GSK’s earnings will grow by 12% a year to end-2026.

So what’s my play here?

It was always hammered home to me as an investment bank trader never to buy into a fast-falling asset. That advice has served me well, so I will not buy more GSK shares right now.

That said, as a long-term investor now I am aware that fundamentally solid stocks – and I see GSK as one – will likely do well over time. So, I will not sell my holding either.

In sum, I will hold my GSK position and see what happens from here, especially with the Q2 results on 31 July.

Of course, there are plenty of other passive income opportunities to explore. And these may be even more lucrative:

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Hikma Pharmaceuticals Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6.8% dividend yield! Consider these 2 ‘secret’ passive income stocks to target a £1,360 payday in 2025

Looking for ways to generate above-average dividend income? These lesser-bought income stocks are worth a close look.

Read more »

Elevated view over city of London skyline
Investing Articles

The M&G dividend yields over 10% — and could get higher!

Christopher Ruane explains why he's upbeat about the long-term outlook for the M&G dividend yield and would happily buy the…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

2 popular UK growth stocks I wouldn’t touch with a bargepole in today’s market

Buying growth stocks can deliver market-beating returns, but this FTSE 250 pair doesn't look like a convincing investment for our…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

10 FTSE shares falling today after President Trump’s tariffs bombshell!

Our writer explains why JD Sports Fashion from the FTSE 100 and a diverse bunch of other UK stocks are…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With value investing back in vogue, I’m taking a leaf out of Warren Buffett’s playbook

With tariffs and trade wars resulting in heightened market volatility, Andrew Mackie takes comfort in Warren Buffett’s words of wisdom.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Around a 1-year high, is there enough value left in Next’s share price to make it worth me buying?

Next’s share price has risen a lot in eight months, but there could still be a lot of value left…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

OMG DYOR but IMO this ‘cool’ FTSE 100 stock offers bangin’ VFM!

Despite being one of the least trendy 50-somethings around, our writer considers how Gen Z could help push this FTSE…

Read more »

Investing Articles

2 cheap FTSE 100 and FTSE 250 growth stocks to consider as stock markets sink

I think these Footsie and FTSE 250 growth shares could be very shrewd buys to consider in the current climate.…

Read more »